{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:39:46Z","timestamp":1785332386509,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41569-020-00439-7","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T18:27:19Z","timestamp":1598984839000},"page":"673-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The COVID-19 pandemic: a catalyst to improve clinical trials"],"prefix":"10.1038","volume":"17","author":[{"given":"Prakriti","family":"Gaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"439_CR1","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1001\/jama.2020.7197","volume":"323","author":"RK Wadhera","year":"2020","unstructured":"Wadhera, R. K. et al. Variation in COVID-19 hospitalizations and deaths across New York City boroughs. JAMA 323, 2192\u20132195 (2020).","journal-title":"JAMA"},{"key":"439_CR2","unstructured":"FDA. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency https:\/\/www.fda.gov\/media\/136238\/download (2020)."},{"key":"439_CR3","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1093\/eurheartj\/ehaa567","volume":"41","author":"M Nicholls","year":"2020","unstructured":"Nicholls, M. COVID-19 and cardiovascular disease. Eur. Heart J. 41, 2727\u20132729 (2020).","journal-title":"Eur. Heart J."},{"key":"439_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018274","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj, S. et al. The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19. JAHA https:\/\/doi.org\/10.1161\/JAHA.120.018274 (2020).","journal-title":"JAHA"},{"key":"439_CR5","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1093\/eurheartj\/ehaa302","volume":"41","author":"S Roux","year":"2020","unstructured":"Roux, S. & Bhatt, D. L. Self-treatment for acute coronary syndrome: why not? Eur. Heart J. 41, 2144\u20132145 (2020).","journal-title":"Eur. Heart J."},{"key":"439_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jacc.2020.05.038","volume":"76","author":"AS Bhatt","year":"2020","unstructured":"Bhatt, A. S. et al. Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic. J. Am. Coll. Cardiol. 76, 280\u2013288 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"439_CR7","first-page":"81","volume":"32","author":"X Wang","year":"2020","unstructured":"Wang, X. & Bhatt, D. L. COVID-19: an unintended force for medical revolution? J. Invasive Cardiol. 32, 81\u201382 (2020).","journal-title":"J. Invasive Cardiol."},{"key":"439_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jacc.2020.05.041","volume":"76","author":"E Bagiella","year":"2020","unstructured":"Bagiella, E., Bhatt, D. L. & Gaudino, M. The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials. J. Am. Coll. Cardiol. 76, 342\u2013345 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"439_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jacc.2015.11.027","volume":"67","author":"T Jatene","year":"2016","unstructured":"Jatene, T. et al. Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX trial. J. Am. Coll. Cardiol. 67, 596\u2013598 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"439_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","volume":"375","author":"DL Bhatt","year":"2016","unstructured":"Bhatt, D. L. & Mehta, C. Adaptive designs for clinical trials. N. Engl. J. Med. 375, 65\u201374 (2016).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-00439-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-00439-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-00439-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:26:40Z","timestamp":1630456000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-00439-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1038\/s41569-020-00439-7","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"1 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.L.B. discloses the following relationships. Advisory Board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences. Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft. Chair: AHA Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute. Honoraria: ACC (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, <i>Harvard Heart Letter<\/i>), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, <i>Journal of Invasive Cardiology<\/i>), <i>Journal of the American College of Cardiology<\/i> (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence\/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, <i>Cardiology Today\u2019s Intervention<\/i>), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees). Other: <i>Clinical Cardiology<\/i> (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company. Royalties: Elsevier (Editor, <i>Cardiovascular Intervention: A Companion to Braunwald\u2019s Heart Disease<\/i>). Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda. P.G. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}